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HSV-1 and HSV-2 are closely related human pathogens that share approximately 50% overall 
sequence homology and cause latent infections recurring as orofacial and genital herpes. Recently 
a novel treatment modality was introduced against HSV-1 utilizing enzymatically synthesized pools 
or swarms of siRNAs. These siRNA swarms trigger the RNAi pathway and inhibit viral replication by 
silencing essential viral genes. Viruses are ideal targets for RNAi therapies. For example, siRNA 
drugs can be developed more rapidly than small inhibitory drugs to combat newly emerged viral 
strains or escape mutants. The antiviral siRNA swarms used in this study target the essential HSV-1 
genes UL27, UL29 and UL54. My aim was to determine whether these same swarms could silence 
the corresponding HSV-2 genes, inhibiting viral replication. The effects of swarms were studied on 
several HSV-2 clinical isolates in mink lung cells (MLCs) and human keratinocytes (HaCaT). Plaque 
titration was used to establish the viral titer in plaque forming units and qPCR was performed for 
the HSV-2 gD gene to determine the genome copy number. All anti-HSV swarms reached 
significant inhibition levels in MLC, the UL29 swarm being the most effective. Inhibitory effects 
were present but less pronounced in HaCaT cells.  
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1 Review of literature 
 
1.1 Herpes simplex viruses 
 
Herpes simplex viruses (HSVs) are human pathogens that belong to the Herpesviridae family. 
There are two species of these viruses, herpes simplex virus 1 and 2 (HSV-1 and HSV-2), which 
mainly cause oral and genital herpes respectively. (Whitley and Roizman 2001; Hukkanen and 
Seppänen 2020.) These viruses are closely related and share 46% overall sequence homology with 
85% identical nucleotides (Kieff et al. 1972). It is believed that HSV-2 evolved from a chimpanzee 
herpes virus whose predecessor diverged from HSV-1 six million years ago. The chimpanzee 
herpes virus then returned to the human lineage two million years ago and became what is known 
today as HSV-2. Because HSVs are old, they have evolved closely together with their human hosts 
and are extremely well adapted to them. (Hukkanen 2020.) 
HSV-1 and HSV-2 consist of a large double stranded DNA genome surrounded by an 
icosapentahedral capsid, an amorphous protein layer called a tegument and an outermost 
envelope (Fig. 1) (Grünewald et al. 2003). Their genome is approximately 152 000–155 000 base 
pairs long and consists of two covalently linked DNA segments with unique sequences designated 
as UL (unique long) and US (unique short). These segments are flanked by inverted repeats. 
(Hayward et al. 1975; Widener and Whitley 2014.)The genome codes for at least 84 proteins which 
can have several functions (Ward and Roizman 1994). HSV needs all of its genes when replicating 





Figure 1. The structure of HSV. The viral genome consists of double stranded DNA contained in an 
icosapentahedral capsid. The capsid is surrounded by amorphous proteins which make up the 
tegument. The tegument is enclosed by an envelope which contains several envelope proteins. 
(Taylor 2010) 
 
HSV-1 and HSV-2 cause latent infections during which they stay dormant in their host for up to 
decades before they reactivate and cause a new infection (Hukkanen 2020). HSV-1 stays latent in 
the trigeminal ganglia while HSV-2 establishes latency in the sacral ganglia (Widener and Whitley 
2014). Latency not only increases the pathogenicity of the virus (Whitley and Roizman 2001), but it 
also allows the virus to remain in the human population by giving rise to predominantly mild, non-
lethal infections (Hukkanen 2020). This in turn has made viral transmission from generation to 
generation effortless (Hukkanen 2020). 
Another distinguishing factor of HSV is its neurovirulence, the ability to infect and replicate in 
neural tissue. Neurovirulence is mediated by the γ134.5 protein whose function affects Eukaryotic 
translation initiation factor 2A (eIF-2A) despite the presence of active Protein kinase R (PKR). As a 
result, even though active PKR may phosphorylate eIF-2A to stop protein synthesis, eIF-2A remains 
dephosphorylated due to the function of γ134.5. This allows protein synthesis to continue in 
neuronal cells, which gives the virus enough time to replicate in the cell before it is eventually 
destroyed. (He et al. 1997; Hukkanen and Seppänen 2020.) In addition to neurovirulence, the 
γ134.5 protein plays a role in preventing cellular defences such as interferon (IFN) induction, 
autophagy and xenophagy (Hukkanen and Seppänen 2020).  
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HSV infections are commonly treated with acyclovir, a synthetic acyclic purine-nucleoside 
analogue, either topically, orally or intravenously (Whitley and Roizman 2001). HSV can also be 
treated with precursor drugs valaciclovir and famciclovir that have better oral bioavailability 
(Balfour 1999). While acyclovir and its precursor drugs can ease disease symptoms and lower 
recurrences of genital herpes when taken orally, these drugs cannot fully prevent viral reactivation 
(Whitley and Roizman 2001). Additionally, there are currently no vaccines available for either 
virus, though several potential HSV-2 vaccines are undergoing development (Johnston et al. 2016).  
 
1.1.1 Herpes simplex virus type 1 
 
HSV-1 mainly causes orofacial herpes with an incubation period of 2 – 12 days (Whitley and 
Roizman 2001). The virus is transmitted through close contact of mucosal surfaces. A primary 
infection occurs when a person seronegative to either HSV-1 or HSV-2 develops an HSV infection. 
A recurrent infection on the other hand describes an infection that is periodically recurring in an 
HSV seropositive individual. (Whitley et al. 1998.) While a primary HSV-1 infection may be 
asymptomatic, some common symptoms of a primary infection include a lesion around the mouth 
area (Fig. 2), swelling of surrounding lymph nodes and fever. The disease usually heals in roughly a 
week and reoccurs at varying frequencies depending on the individual. Lack of symptoms during a 





Figure 2. A herpes lesion on the lip caused by HSV-1. Infections by HSV-1 may be asymptomatic 
but common symptoms include lesions around the mouth area which typically heal within a week. 
The disease reoccurs at varying frequencies depending on the individual. (Centers for Disease 
Control and Prevention 2010) 
 
HSV-1 infections occur in both developed and developing countries. The prevalence of the virus is 
affected by several factors such as geographic region, age and sex. In 2016, prevalence was the 
highest in the South-East Asia region for oral HSV-1 infections and the Americas followed by 
Europe for genital HSV-1 infections. During the same year, in the global population aged 0 – 49, 
3,6 billion people, or an equivalent of 63,6% of the global population, harboured an oral HSV-1 
infection while 192 million people aged 15 – 49 or an equivalent of 5,2% of the entire population 
had a genital HSV-1 infection. The number of people infected with both oral and genital HSV-1 
increased with age. (James et al. 2020.) 
Aside from orofacial herpes, an increasing number of genital herpes infections are also caused by 
HSV-1 (Tuokko et al. 2014; Looker et al. 2015). This increase is hypothesized to be caused by 
changes in sexual behaviour. Oral sex has likely increased in frequency and this, coupled with the 
overall decrease in HSV-2 genital herpes cases offers one explanation for the increase in the 
number of HSV-1 genital herpes cases. (Hukkanen and Seppänen 2020.)   
Oral and genital herpes are the most common diseases caused by HSV-1 but transmission of the 
virus can also lead to infections in ocular tissue (Rowe et al. 2013) and the central nervous system 
(CNS) or to generalized infection in neonates or immunocompromised individuals (Hukkanen and 
Seppänen 2020). Ocular tissue infection can occur in the lids, cornea, retina, uveal tract and 
conjunctiva (Rowe et al. 2013). Conjunctivitis with possible inflammation of the eyelids and 
corneal epithelial dendritic lesions are typical manifestations of primary ocular infections which 
occur rarely and mostly in the younger population (Darougar et al. 1985). More commonly ocular 
infections result from viral reactivation of latent infection in the trigeminal ganglia. When this 
reactivation occurs in the ophthalmic branch of the trigeminal ganglion viral shedding can occur in 
the corneal surface resulting in infectious epithelial keratitis (IEK) or herpes stromal keratitis (HSK). 
(Shimeld et al. 1990; Rowe et al. 2013.) The difference between the two, is that lesions are 
restricted to the corneal epithelium in IEK, while in HSK lesions can appear in the stroma or the 
overlying epithelium (Darougar et al. 1985). Viral replication in the epithelium results in epithelial 
cell destruction. Overall, HSV-1 caused recurrent keratitis can manifest as HSK, epithelial dendritic 
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lesions and geographic epithelial lesions (Labetoulle et al. 2005). HSK is especially problematic 
because the risk of disease recurrence is significantly increased by previous instances of infection. 
Additionally, HSK recurrence may result in irreversible corneal damage and eventual blindness. 
(Wilhelmus et al. 1998.) 
HSV infections in the CNS include herpes simplex encephalitis (HSE) and neonatal herpes 
(discussed more in the chapter Herpes simplex virus type 2) which generally occur at the age of 
over 3 months or under 1 month respectively. Both infections cause severe neurologic damage 
and can lead to death. (Widener and Whitley 2014.) HSE is most commonly caused by HSV-1 
(Hukkanen and Seppänen 2020) and leads to brain tissue necrosis by causing inflammation, 
congestion and haemorrhages (Widener and Whitley 2014). Patients may experience 
disorientation, changes in behaviour and seizures. Approximately one third of HSE cases are 
caused by primary infection while the rest are attributed to recurrent infection. The resulting 
infection can travel to the brain through the trigeminal or olfactory nerve pathways. Even when 
the infection is cleared patients may be left with lasting sequelae such as dementia, learning and 
memory difficulties. (Hukkanen and Seppänen 2020.) Some less dangerous manifestations of HSV 
caused CNS infections include HSV aseptic meningitis and radiculopathies (Widener and Whitley 
2014). 
 
1.1.2 Herpes simplex virus type 2 
 
HSV-2 infections most commonly lead to genital herpes, a disease transmitted through sexual 
contact. The incubation period of HSV-2 is the same as for HSV-1, ranging from 2 – 12 days. 
Symptoms for primary genital herpes include macules and papules as well as vesicles, pustules and 
ulcers. Recurrent infection in males causes 3 – 5 vesicles in the penis shaft while in females 
symptoms appear as ulcerating-vesicle lesions in the genital area or as vulvar irritation. Absence of 
symptoms does not prevent the virus from being transmitted from one person to another as virus 
shedding occurs even in asymptomatic infection. (Whitley and Roizman 2001.) Typically, recurrent 
infection causes milder symptoms that can last 1 – 2 weeks. Additionally, recurrence of genital 
herpes depends on the virus causing it, as genital herpes caused by HSV-2 reoccurs at higher 
frequencies than genital herpes caused by HSV-1. (Hukkanen and Seppänen 2020.) 
HSV-2, like HSV-1, occurs worldwide in both developed and developing countries (James et al. 
2020). Because HSV-2 transmits sexually, seroconversion usually only occurs once a person has 
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become sexually active (Whitley and Roizman 2016). Geographical region, sex and the number of 
sexual partners all play a role in HSV-2 acquisition. Females are more likely to contract the virus 
than males, presumably because they have more mucosal surface. (Widener and Whitley 2014.) In 
2016 an estimated 491,5 million people worldwide aged 15 – 49 were infected with HSV-2, which 
equates to 13,2% of the global population. Prevalence was the highest in the African region and 
the number of infected individuals increased with age though this number was also affected by 
differences in population sizes. Additionally, the highest prevalence across all regions was 
observed in women. (James et al. 2020.) 
HSV-2 significantly increases human immunodeficiency virus (HIV) transmission as the risk to 
acquire HIV is up to threefold higher when a person is infected with HSV-2 (Looker et al. 2017). 
This is because ulcers, even microscopic ones, caused by genital herpes allow HIV to enter the 
body and cause infection. Ulcers caused by herpes also lead to increased levels of CD4 (cluster of 
differentiation 4) lymphocytes that HIV can then target and destroy. (Wald and Link 2002.) 
Additionally, HSV-2 is able to upregulate HIV replication which in turn increases HSV-2 recurrence, 
creating a vicious cycle for infection (Margolis et al. 1992; Widener and Whitley 2014).  
Much like HSV-1, infections by HSV-2 can lead to infections in the CNS, especially in neonates and 
in immunocompromised individuals. Neonatal herpes is predominantly caused by primary HSV-2 
infections and typically transmission occurs through the birth canal from either symptomatic or 
asymptomatic genital herpes. When the causal agent of infection is HSV-1, neonatal herpes only 
occurs during primary infection. Rarely is neonatal herpes caused by an intrauterine HSV infection. 
(Hukkanen and Seppänen 2020.) The development of neonatal herpes is dependent on the timing 
of the mother’s HSV acquisition. Thus, a newborn is least likely to contract HSV when the mother 
acquires an HSV infection prior to labour and the chance increases when the mother’s acquisition 
of infection occurs near labour. (Brown et al. 1997.) Overall, the majority of neonatal herpes 
infections occur during the peripartum period, followed by the postpartum period (Widener and 
Whitley 2014).  
Neonatal herpes can also be classified based on symptoms. The SEM form of disease is 
characterised by lesions on the skin, eyes or mouth. Disseminated disease involves multiorgan 
infection that causes newborns to experience lethargy, irritability, seizures and respiratory distress 
among other symptoms. The organs involved include the skin, mouth, eyes, lungs, liver, adrenal 
gland as well as the CNS. Disseminated disease can be accompanied by encephalitis or manifest on 
its own as neonatal herpes. Encephalitis shares many of the same symptoms as disseminated 
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disease along with temperature instability, poor feeding and bulging fontanel and pyramidal tract 
signs. (Widener and Whitley 2014.) Neonatal herpes can be prevented by a caesarean section but 
more commonly transmission is prevented by giving the mother an antiviral prophylactic before 
labour. Additionally, antibodies gained from the mother help relieve the symptoms of the 
newborn. (Hukkanen and Seppänen 2020.)  
 
1.1.3 Herpes simplex virus infection biology 
 
HSV infects and attaches onto cells through glycoproteins B, C and D (gB, gC and gD). 
Glycoproteins B and C initiate the attachment by interacting with cell surface heparan sulfate 
while gD binds to the HSV entry receptor. Out of all HSV receptor molecules HVEM (herpesvirus 
entry mediator) and HveC (herpesvirus entry mediator C) act as receptors for both HSV-1 and HSV-
2 whereas HveB (herpesvirus entry mediator B) is mainly an HSV-2 receptor. (Hukkanen and 
Seppänen 2020.) HveC and HveB which are also known as Nectin-1 and Nectin -2 respectively 
belong to the immunoglobulin G superfamily and both act as intracellular adhesion molecules 
(Campadelli-Fiume et al. 2000). After binding to an HSV receptor, the envelope of the virus fuses 
with the cellular plasma membrane and the capsid is transported along microtubules to the 
nucleus (Fig. 3). The viral DNA is released into the nucleus through the nuclear pore. Gene 
expression takes place in three phases and is initiated by VP16 (TIF), an HSV transactivator 
protein, which enters the nucleus and initiates the transcription of alpha (immediate early) genes. 
The cellular transcription factors and other proteins are also involved in transcription initiation. 
(Roizman and Whitley 2013; Hukkanen and Seppänen 2020.) Expression of alpha genes yields 
alpha proteins that initiate the transcription of beta (early) genes. Beta proteins then initiate the 
viral DNA replication, which enables the expression of the final set of gamma or late genes. 





Figure 3. The different stages of acute and latent infection by HSV-1. In acute infection (1.) the 
virus binds to an HSV receptor after which the viral envelope fuses with the cellular plasma 
membrane and the capsid is transported to the nucleus (A). The DNA is released into the nucleus 
where viral gene expression takes place in three stages initiated by VP16, an HSV transactivator 
protein (B). The first round of gene expression yields alpha proteins which induce the expression of 
beta genes. Beta proteins then induce the viral DNA replication, thus allowing the expression of 
gamma genes (C). Latent infection by HSV-1 (2.) is established in sensory neurons in the trigeminal 
ganglia where the virus enters the nucleus of the neuron after being transported through the 
connecting axon from the initial site of infection in the epithelial cells (G). Viral DNA remains as a 
circularized DNA molecule in the nucleus and does not integrate into the host genome (H). The 
production of viral proteins and infective particles is repressed and only LAT-RNA, and the 
microRNAs encoded in its sequence, are continuously expressed in the cell, preventing it from 
undergoing apoptosis (H). (Marcocci et al. 2020)   
 
Alpha proteins are mainly involved in regulating viral replication (Widener and Whitley 2014). Beta 
proteins are responsible for DNA synthesis and packaging (Widener and Whitley 2014), while 
gamma proteins mostly consist of structural virion proteins such as capsid, tegument and 
envelope proteins (Hukkanen and Seppänen 2020). Many virulence factors are also expressed 
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under gamma regulatory conditions. The viral capsid is formed in the nucleus and virions gain their 
first envelope from the inner nuclear membrane. However, the initial envelope is most likely lost 
once HSV particles leave the nucleus. Virions then make their way to the cell surface and gain their 
final envelope during this process while utilizing cellular membranes and vesicles to exit the cell. 
(Mettenleiter et al. 2013; Hukkanen and Seppänen 2020.) 
As mentioned before, a distinguishing factor of HSV infections is latency which is established in 
sensory neurons when the virus is transported from the epithelial cells in the initial site of 
infection through the connecting nerve axon into the nucleus of the neuron (Whitley and Roizman 
2001; Hukkanen and Seppänen 2020). The virus does not integrate into the host genome but 
remains as an episomal DNA molecule in the nucleus instead. No infective viral particles or 
proteins are produced in the nerve cell and only the latency associated RNA (LAT-RNA) is 
continuously expressed. (Roizman and Whitley 2013.) The LAT-RNA keeps the host neuronal cell 
alive by preventing it from undergoing apoptosis (Perng et al. 2000). Numerous microRNAs 
(miRNA) are coded in the LAT genomic region, both in HSV-1 and HSV-2 (Umbach et al. 2008; Jurak 
et al. 2010). The LAT-RNA can also be activated by different stimuli such as UV-light, stress or 
other infections which causes viral replication to reactivate. Typically, this takes place in one or a 
few neuronal cells at a time and results in the eventual destruction of the neuronal cell. After this 
the newly synthesized virions travel back through the axon to the initial site of infection where 
they cause a recurrent infection in the epithelium. (Roizman and Whitley 2013; Hukkanen and 
Seppänen 2020.)  
 
1.1.4 Host responses to HSV infection 
 
The immune system of vertebrates consists of two components; innate immunity which an 
individual is born with and adaptive immunity which develops via confrontations with pathogens. 
Host cell responses are shut off after HSV infects a cell. As a result, many host cell proteins are 
degraded, some of their gene expression is repressed and apoptosis is prevented (Paavilainen 
2017). HSV has a remarkable ability to affect and evade both of these systems as it has over 20 
ways to interfere with and hide from host immune responses. It can for example prevent the 
identification by and functions of many immune cells including macrophages, dendritic cells, 
cytotoxic and CD4+ T cells, as well as natural killer (NK) and Lymphokine-activated killer (LAK) cells. 
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Additionally, HSV can prevent IFN responses, apoptosis and necroptosis and evade Toll like 
receptors (TLRs). (Hukkanen and Seppänen 2020.)  
HSV achieves T cell evasion by inhibiting Major histocompatibility complex (MHC) class I 
presentation of the virus. More specifically, HSV’s Infected cell protein 47 (ICP47) prevents antigen 
presentation to CD8+ T cells by preventing peptide loading to MHC. (Früh et al. 1995; Hill et al. 
1995.) While T cell evasion leaves HSV susceptible to NK cells at least HSV-2 has the ability to 
interfere with their function (Bellner et al. 2005). HSV also interferes with host responses through 
several of its glycoproteins. HSV’s glycoprotein C (gC) for example blocks the complement system 
component C3b which in turn inhibits the activation of the alternative and classical pathways of 
the complement system (Fries et al. 1986). In addition, gC together with glycoprotein E (gE) have 
the ability to shelter other HSV glycoproteins blocking the virus’s recognition by antibodies (Hook 
et al. 2008). Lastly gE and glycoprotein I (gI) of HSV inhibit antibody mediated adaptive immune 
responses by binding together and forming an Fc receptor that further binds to the Fc part of 
immunoglobulin G (IgG) (Johnson et al. 1988).  
 
1.2 RNAi based therapies 
 
RNA interference (RNAi) is a post transcriptional gene silencing mechanism first discovered in 
Caenorhabditis elegans in 1998 by Andrew Fire and Craig Mello. This discovery established that 
non-coding RNAs play an essential role in regulating gene expression in multicellular organisms 
(Fire et al. 1998). Later it was reported that RNAi could be triggered in mammalian cells by short 
21-22 nucleotide (nt) long double stranded RNA (dsRNA) molecules without an induction of non-
specific IFN responses (Elbashir et al. 2001). Short interfering RNAs or siRNAs have become an 
essential part of biological research because of their ability to silence any gene based on sequence 
complementarity. More importantly the discovery of siRNAs allows for the potential to develop 
versatile drugs that can target proteins previously considered undruggable. The sequence specific 
nature of RNAi based drugs also comes with the benefit that siRNAs can be retargeted without 




1.2.1 RNAi pathway through the lens of microRNA function 
 
In mammalian cells the RNAi pathway starts in the nucleus with the transcription of primary 
microRNAs (pri-miRNAs) that are cleaved by a protein complex called Microprocessor (Fig. 4). 
Microprocessor comprises proteins Drosha and DiGeorge syndrome critical region gene 8 (DGCR8) 
and the cleavage produces short hairpin RNAs (shRNAs) termed pre-miRNAs. (Lee et al. 2002; 
Gregory et al. 2004.) These RNAs are bound by Exportin 5 and transported to the cytoplasm (Yi et 
al. 2003) where Dicer and TAR RNA binding protein (TRBP) engage with it allowing for the cleavage 
of the pre-miRNA terminal loop by Dicer (Chendrimada et al. 2005). This in turn induces the 
formation of RLC (the RNA-induced silencing complex (RISC) -loading complex) with one of four 
Argonaute (Ago1-Ago4) proteins (Meister et al. 2004; Maniataki and Mourelatos 2005). RLC loads 
the antisense strand, also called the guide strand, of the miRNA onto the Argonaute protein while 
the sense or passenger strand is subsequently discarded and degraded (Matranga et al. 2005). 
With this the mature RISC, which comprises an Argonaute protein and the guide RNA, is ready to 
bind to messenger RNAs (mRNAs) that are complementary to its guide strand and inhibit their 
translation with a key mediator protein called GW182 (Eulalio et al. 2008; Takimoto et al. 2009). 
RISC achieves this by inducing sequestration of mRNAs into cytoplasmic P or GW bodies or by 
otherwise promoting mRNA degradation (Liu, Rivas, et al. 2005; Liu, Valencia-Sanchez, et al. 2005; 
Gibbings et al. 2009). Ago2 bears particular interest in the RNAi pathway as it is able to intrinsically 
cleave mRNAs (Liu et al. 2004; Meister et al. 2004). Additionally, an mRNA need not be fully 
complementary to the guide strand as it is enough that complementarity spans the seed region 






Figure 4. The RNAi pathway of miRNAs and siRNAs. In the nucleus of mammalian cells pri-miRNAs 
(primary microRNAs) are transcribed and subsequently cleaved by a protein complex called 
Microprocessor which comprises proteins Drosha and DGCR8. Cleavage produces sh-RNAs (short 
hairpin RNAs), termed pre-miRNAs, which are transported to the cytoplasm by Exportin 5. Here 
proteins TRBP and Dicer associate with the pre-miRNA which allows Dicer to cleave the terminal 
loop of the RNA. After this RLC (RISC loading complex) is formed with one of four Ago proteins 
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(Ago1-Ago4). RLC loads the antisense or the guide strand of the miRNA onto the Ago protein and 
the sense or passenger strand is discarded and degraded. The mature RISC, which comprises the 
Ago protein and the silencing guide strand, is formed following this event and together they bind to 
mRNAs complementary to the guide RNA of RISC. Along with a key mediator protein GW182 the 
transcription of bound mRNAs is prevented and they are sequestered to cytoplasmic P or GW 
bodies or are otherwise degraded. Exogenous siRNAs which enter cells through endocytosis and 
undergo endosomal escape are also able to induce RNAi. Similarly to miRNAs, siRNAs associate 
with TRBP and Dicer which induces the formation of RLC with the Ago2 protein. The guide strand is 
selected and loaded onto Ago2 and the mature RISC binds mRNAs complementary to its guide RNA. 
Ago2 which harbours intrinsic slicer activity cleaves the mRNA thus silencing it and preventing its 
translation into protein. m7G denotes 7-methylguanosine. (Setten et al. 2019) 
 
1.2.2 RNAi triggers 
 
RNAi can be triggered by synthetic small interfering RNAs that are usually designed to target a 
single mRNA (Elbashir et al. 2001). After entering the cell through endocytosis and undergoing 
endosomal escape, the synthetic siRNAs enter the silencing pathway by directly interacting with 
Dicer and TRBP (Fig. 4) (Haase et al. 2005; Wittrup et al. 2015). RLC is formed following this 
interaction which then induces guide strand selection, mature RISC production and subsequent 
gene silencing (Snead et al. 2013).  
Synthetic RNAi triggers, which are generally perfectly base paired dsRNAs or short hairpin RNAs 
(shRNAs), may have a variety of structural motifs (Setten et al. 2019). Their lengths vary between 
15 and 30 bp, since RNA triggers shorter than 15 bps cannot engage with the RNAi machinery 
while ones over 30 bps may induce nonspecific cytotoxic effects (Kim et al. 2005). There are also 
functional differences between siRNAs varying in length. siRNAs of 25/27 nt or 25 bps act as 
substrates for Dicer (DsiRNAs) and have better silencing efficacy and a higher chance of antisense 
strand selection than 21/21 nt or 19 bp siRNAs which are non-Dicer substrates (Snead et al. 2013). 
The latter siRNAs  have better metabolic stability when not encapsulated in nanoparticles because 
their nature as non-Dicer substrate allows for the entirety of the siRNA and its 5’ terminal 
phosphates to be chemically modified to achieve this (Parmar et al. 2016). All in all, different 
structural motifs serve different purposes. Some motifs are more efficient for RNAi processing, 
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some aid with guide strand selection between antisense and sense strands and some are better 
equipped to handle chemical modifications (Setten et al. 2019).  
RNAi triggers may also include chemical modifications that are widely used in the development of 
RNAi drugs and serve two main purposes. Firstly, their inclusion helps RNAi triggers avoid 
activating immune responses and secondly, they prevent RNAi triggers from being degraded by 
endogenous exo- and endonucleases (Robbins et al. 2007; Bramsen et al. 2009). Chemical 
modifications may serve other additional purposes such as enhancing correct guide strand 
selection during RISC loading, reducing off-target effects by improved sequence selectivity and 
aiding in delivery to target sites by modifying the chemical and physical properties of the RNAi 
trigger (Bramsen et al. 2009; Janas et al. 2018; Setten et al. 2019). Some common chemical 
modifications to the backbone of the RNAi trigger include the incorporation of 2ʹ-O-methyl, 2ʹ-
fluoro (Levanova et al 2020) and 2ʹ-O-(2-methoxyethyl) groups (Khvorova and Watts 2017). These 
modifications improve nuclease resistance and reduce the induction of immune responses and off 
target effects (Bramsen et al. 2009; Ge et al. 2010; Khvorova and Watts 2017; Levanova et al. 
2020). 
 
1.2.3 Delivery of RNAi triggers 
 
One of the biggest challenges of RNAi based therapies pertains the effective delivery of RNAi 
triggers to their target cells. These challenges are posed by the large size and negative charge of 
dsRNAs that cannot be addressed with chemical modifications alone and that affect systemic 
circulation, tissue penetration, cellular uptake and endosomal escape (Wittrup and Lieberman 
2015; Setten et al. 2019). The first delivery issue is faced during administration to the bloodstream 
where naked RNAs are prone to nuclease degradation and can trigger innate immune responses 
(Layzer et al. 2004; Sioud 2005). RNAi triggers may also interact with serum components which can 
hinder their delivery to target sites (Malek et al. 2009). However, serum components such as 
lipoproteins can also be exploited by delivery systems to aid cellular uptake (Wolfrum et al. 2007).  
The next challenge is encountered when naked RNAs enter the kidneys where they are too small 
in size to prevent their filtration from the circulation into urine (Huang et al. 2011). Thus, delivery 
systems must counter RNA clearance from the body while also avoiding being degraded in kidneys 
themselves (Zuckerman et al. 2012). Once RNAs have cleared their way through the kidneys they 
must exit the bloodstream and enter their target tissues through the endothelium. Delivery 
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becomes more difficult when tissue endothelia is continuous because lack of permeability leaves 
few openings for RNAs and their possible delivery vehicles to diffuse from the bloodstream into 
target cells. (Kanasty et al. 2013.) 
The last two challenges are faced during cellular uptake and loading onto the RISC machinery. RNA 
molecules are too large in size to cross cell membranes and cellular uptake usually occurs through 
endocytosis (Wittrup and Lieberman 2015). This process can be assisted with targeting ligands that 
aid RNA internalization by interacting with cell surface receptors (Yu et al. 2009). If RNAs enter 
cells through endocytosis they must be released by the endosome into the cytoplasm. Endosomal 
escape is inefficient by itself, and endosome membrane disruption must be enhanced for higher 
levels of RNAs to be released into the cytoplasm (Wittrup and Lieberman 2015). In the cytosol RISC 
guide strand selection and loading happens to the RNA strand whose 5’ end is most unstably 
hybridized. Because this end is crucial for RISC loading, conjugate delivery material attachment to 
the 5’ end of the antisense strand is usually avoided. (Schwarz et al. 2003.) Other chemical 
modifications to the RNAi trigger backbone must also be carefully chosen to prevent mistakes in 
antisense strand selection as the guide strand during RISC loading (Kanasty et al. 2013).   
Taking into account all of the delivery issues mentioned above, there has been a dire need to 
develop chemical excipients to overcome these challenges such as nanoparticles, lipid 
nanoparticles (LNPs) and nucleic acid nanostructures as well as polymers, dendrimers, exosomes 
and GalNAc- conjugated melittin- like peptides (NAGMLPs). For specific targeting purposes siRNAs 
have been attached to ligands such as aptamers, antibodies, peptides and small molecules like 
GalNAcs. (Setten et al. 2019.)  
 
1.2.4 RNAi based therapies against diseases 
 
The convenience of RNAi based therapeutics lies in the fact that, in theory, any disease-causing 
gene in any cell type can be silenced by RNAi triggers because all cells contain the necessary RNAi 
machinery. As such, potential drug candidates are much more numerous than enzymes and 
receptors targeted by small molecule drugs. Careful target selection in RNAi based therapies is 
important because knockdown of genes with non-redundant functions may lead to anticipated or 
unanticipated direct toxicities. (Wittrup and Lieberman 2015.) However direct toxicities do not 
necessarily occur if the target gene has a null or hypomorphic mutation which causes no 
symptoms or is even protective for the patient (Cohen et al. 2006). Conversely in certain diseases 
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it might be possible and even beneficial to silence genes that would otherwise be needed in a 
healthy individual. While silencing such genes is undoubtedly risky, exploring this research avenue 
might still be worthwhile. (Tabernero et al. 2013; Wittrup and Lieberman 2015.)  
As mentioned before, delivery is one of the biggest issues hindering the development of RNAi 
based therapies. This is because delivery vehicles must work in a clinical setting. Currently, 
hepatocytes and the liver are the most accessible targets and delivery to them is no longer seen as 
a problem (Akinc et al. 2010; Shi et al. 2011; Wittrup and Lieberman 2015). Following these target 
sites are the skin, mucosa and eyes which can be accessed through topical application or injection. 
The most suitable delivery method for most of these targets seems to be cholesterol-conjugation 
(Wittrup and Lieberman 2015). 
RNAi based therapies have been in clinical development for a wide range of diseases including 
viral infections (discussed in the next chapter), cancer as well as cardiovascular, ocular and rare 
genetically inherited diseases (Setten et al. 2019). An important example of a successful RNAi drug 
used in clinical settings is patisiran (Onpattro, Alnylam Pharmaceuticals). This siRNA drug is an FDA 
approved medication used for the treatment of transthyretin (TTR) amyloidosis, a rare inherited 
neurodegenerative disease. This life-threatening disease is caused by deposition of TTR amyloids 
in the peripheral nervous system and organs such as the heart and gastrointestinal tract. (Adams 
et al. 2017.) TTR proteins are mainly produced in the liver and can have over 120  hereditary ATTR 
(hATTR) disease causing mutations (Holmgren et al. 2008; Rowczenio et al. 2014).  
Until the development of patisiran, treatment options for hATTR were limited. Small molecules 
were used to stabilize TTR tetramers in their native conformation but this only worked to slow 
disease progression and better treatment options were desperately needed. (Ando et al. 2013; 
Adams et al. 2018.) Patisiran was developed to silence both wild type and mutated TTR genes in 
hepatocytes by using a siRNA that targets the 3’ untranslated region in the TTR mRNAs (Coelho et 
al. 2013). The target site was chosen because it is believed to be more homologous across the 
patient population. By targeting this site a wide range of TTR mRNA variants could be silenced. 
(Butler et al. 2016.) Contrary to many siRNA drugs undergoing clinical development patisiran’s 
formulation does not rely on extensive chemical modifications, metabolic stabilization or a 
targeting ligand. Instead, the siRNA is encapsulated into a lipid nanoparticle that has been 
designed for efficient uptake by hepatocytes. (Coelho et al. 2013; Adams et al. 2018.) While 
patisiran as a drug brings hATTR patients new hope that disease progression can be halted, the 




1.2.5 RNAi based therapies against viral infections 
 
RNAi, while a means of gene regulations also acts as a natural antiviral defence system used by 
both plants and animals such as insects and nematodes (Li and Ding 2006; Zhang and Qu 2014; 
Chin et al. 2017). When used for antiviral defence the siRNA pathway is utilized to process viral 
RNA into virus derived small RNAs (vsRNAs). These RNAs are naturally complementary and specific 
to the viruses they originate from and can even be amplified by the host to enhance RNAi 
mediated antiviral defence. (Chin et al. 2017.) Whether the mammalian siRNA pathway also acts 
as an antiviral defence mechanism is still under controversy and requires further investigation (Seo 
et al. 2013; Gantier 2014).  
In theory the use of RNAi as an antiviral treatment is ideal because viruses replicate in high 
numbers, they are dependent on a limited set of genes and the target genes are usually 
nonhomologous to human genes. RNAi based antiviral therapies also have an advantage in 
development time because it would be faster to develop a siRNA against a newly isolated virus 
than it would be to develop a small inhibitor drug. Additionally, even if a virus develops resistance 
to a siRNA drug or otherwise mutates, the sequence of the siRNA can be readily altered to match 
the mutated virus. (Blake et al. 2012.) 
Generally speaking, RNAi is targeted against genes that are essential for viral infection, replication 
and overall survival. Target genes need not be within the virus itself and instead RNAi can be used 
to silence host genes that are essential for the virus but not the host itself. Such targets include 
surface receptor encoding genes that the virus needs for cell entry or genes related to intracellular 
viral replication. While tampering with regular host gene function carries its own risks, targeting 
host genes instead of viral genes is may be an attractive option when the virus mutation rate is 
high. (Blake et al. 2012.)  
RNAi targeting occurs in a sequence-specific manner and as a result of its high specificity off-target 
effects are limited. This makes siRNA drugs generally well tolerated, compatible with other 
antiviral treatments and potentially well suited for long-term and prophylactic therapies. (Alvarez 
et al. 2009; Zamora et al. 2011; Chin et al. 2017.) Because it is RNA that is cleaved during the RNAi 
process, RNA viruses whose replication occurs in the cytoplasm are especially susceptible to gene 
silencing by this mechanism (Stein et al. 2011; Suhy et al. 2012). Since one siRNA molecule is able 
to silence multiple target mRNAs, off-target effects can be further reduced by using siRNA drugs in 
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low concentrations. Thus, siRNA drugs need not be administered in a proportionate amount to the 
virus for treatments to be effective. (Suhy et al. 2012; Chin et al. 2017.) It is important to note that 
siRNA drugs by themselves can trigger an immune response through the IFN pathway and this 
effect is usually undesirable (Alvarez et al. 2009). However, the IFN response can also aid in viral 
clearance and studies have been conducted to determine whether the immune response 
triggering trait of RNAi drugs could be exploited in a combination therapy that elicits viral 
clearance both through the RNAi pathway and the IFN pathway (Ebert et al. 2011; Chen et al. 
2013).  
Finally, RNAi can not only be utilized as a treatment itself but can be used as a screening method 
to search for potential new genes whose function is essential for the virus. These essential viral 
genes can then act as potential targets for antiviral drug development. In fact, siRNA and shRNA 
based libraries can be used as genome wide screening tools to study the biology of viruses as a 
whole. (Blake et al. 2012; Snijder et al. 2012.) The principle of screening is simple and involves the 
transfection of seeded cells with siRNAs or shRNAs and the subsequent infection of cells with the 
virus under study. If cells show no signs of infection, then a gene vital for viral replication has been 
silenced. Typically, siRNAs are transfected into cells using a liposome based delivery system while 
shRNAs transfection happens through viral or other vectors. (Blake et al. 2012.) 
RNAi has been used to inhibit several viruses in both cell culture, animal models and clinical trials. 
Some of these viruses include HSV, respiratory syncytial virus (RSV), hepatitis B virus (HBV), 
hepatitis C virus (HCV), human papillomavirus (HPV), HIV, influenza and Ebola (Watanabe et al. 
2006; Zhou et al. 2007; Sima et al. 2008; DeVincenzo et al. 2010; DiGiusto et al. 2010; Dunning et 
al. 2016; Paavilainen et al. 2017; Yuen et al. 2020). 
 
1.3 Synthesis of antiviral siRNA swarms 
 
Therapeutic siRNAs can be synthesized in three different ways: enzymatically, chemically or using 
expression vectors or cassettes. Chemical siRNA synthesis starts with the production of a single 
stranded RNA (ssRNA) through automated solid-phase synthesis, which yields ribonucleoside 
phosphoramitides. Thereafter, RNA duplexes are formed by hybridization of the produced ssRNAs. 
Each produced ssRNA is tested by matrix-assisted laser desorption-ionization mass spectrometry 
before siRNA duplexes are formed. siRNAs themselves are also tested for proper annealing by 
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running them through non-denaturing gel or capillary electrophoresis. (Levanova and Poranen 
2018.) 
Expression cassettes can also be utilized for siRNA production (Brummelkamp 2002). These 
cassettes are delivered into cells via plasmids or viral vectors (Levanova and Poranen 2018) and 
incorporate a polymerase III promoter followed by an shRNA sequence in its DNA form and a 
transcription stop signal (Brummelkamp 2002). Once inside the cell, the shRNA is transcribed from 
the cassette and cleaved by Dicer to produce the desired siRNAs which can then associate with 
RISC and induce silencing of target genes (Brummelkamp 2002). 
In enzymatic siRNA production, synthesis takes place in vitro from a vector that contains the DNA 
template sequence for the desired siRNA and a T7 polymerase promoter (Levanova and Poranen 
2018). The T7 DNA-dependent RNA polymerase (DdRp) transcribes both sense and antisense 
strands of these DNA sequences. Thereafter the produced ssRNAs are annealed. (Sohail 2003.) The 
T7 DdRp adds a leader sequence to the 5’ end and possibly random nucleotides to the 3’ end of 
the ssRNA molecules (Sohail 2003) as well as a triphosphate also to the 5’ end (Kim et al. 2004). 
However, the leader sequence can be cleaved off by deoxyribozyme (Sohail 2003) and IFN 
induction of the 5’ triphosphate can be nullified by treating ssRNAs with alkaline phosphatase (Kim 
et al. 2004). Conversely, the random nucleotides at the 3’ end do not have harmful effects on the 
safety and efficacy of produced siRNAs (Sohail 2003). 
Each mentioned approach comes with its advantages and disadvantages. Chemical synthesis for 
example is still relatively costly despite synthesis costs per nucleotide decreasing vastly during the 
past years. The advantage of chemical synthesis is that it produces defined sequences of ultrapure 
siRNAs in large quantities which are suitable for use in clinical trials, for example. Expression 
vectors on the other hand are more suited for long term siRNA production. Traditional enzymatic 
siRNA synthesis suffers from limited siRNA yield due to inefficient hybridization that produces 
inactive siRNAs. This is especially true in the case of long ssRNAs which form tertiary structures 
that prevent the annealing of complementary strands into an RNA duplex. However, enzymatic 
siRNA synthesis has the advantage of rapid, low-cost production and can be used as a screening 






1.3.1 siRNA swarm design and enzymatic synthesis 
 
Instead of using one single siRNA to silence a gene of interest, a mixture of siRNAs with differing 
sequences that target the same gene can be used for silencing purposes. These pools or swarms of 
enzymatically synthesized siRNAs have several advantages over single site siRNAs, especially when 
used for antiviral purposes. Enzymatic synthesis is fast and robust, which means that in the case of 
a sudden virus outbreak antiviral siRNA swarms can be produced rapidly. Because siRNA swarms 
cover a larger area of the viral genome, they are more protective than short single site siRNAs. 
(Levanova and Poranen 2018.) Swarms can also be used against viruses with high mutation rates, 
as the mixture of siRNAs will more effectively inhibit the virus while preventing the generation of 
new escape mutants (Gitlin et al. 2005). Lastly, siRNA swarms have the potential to be more highly 
tolerated with reduced off target effects, because each individual siRNA in the mixture is present 
at very low concentrations (Aalto et al. 2007; Romanovskaya et al. 2012; Paavilainen et al. 2016, 
2017). 
As mentioned before, siRNAs have been used to target several viruses. Before antiviral siRNA 
production takes place, the sequences of these siRNAs must be carefully designed and selected in 
silico. Typically, siRNAs are targeted against essential genes in highly conserved areas in the viral 
genome. This is done to achieve maximal antiviral efficacy while reducing off-target effects. 
Sequences that match closely with human or model animal transcripts are excluded with the use 
of specific filters. (Levanova and Poranen 2018.) Additional structure and sequence-based 
algorithms are also utilized to select siRNA sequences with the highest functionality (Reynolds et 
al. 2004; Levanova and Poranen 2018). Generally speaking, enzymatic siRNA swarm production 
follows the same in silico steps as single site siRNAs synthesis except for the final step of using of 
algorithms to find the most highly functional sequences. This step is not required in swarm 
production because swarms cover a much larger highly conserved area in the genome. (Levanova 
and Poranen 2018.) 
Following in silico sequence design, the antiviral siRNA swarms complementary to the chosen 
target sequence can be produced. A single tube enzymatic synthesis platform has been developed 
by Aalto et al. (2007) where dsRNA production starts with the cloning of the target DNA template 
into a suitable vector under a T7 polymerase promoter (Fig 5.). The T7 DdRp then transcribes the 
DNA template into ssRNAs, which bacteriophage Phi6 RNA-dependent RNA polymerase (RdRp) 
uses for the production of the complementary strand by synthesizing the minus strand starting 
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from the 3’ end of the original ssRNA plus strand.  The use of Phi6 RdRp circumvents the inefficient 
ssRNA annealing step of traditional enzymatic siRNA synthesis which requires heating at a high 
temperature for the denaturing of secondary and tertiary structures. (Aalto et al. 2007.) 
Additionally, the enzyme lacks template specificity which means that it can also be used to 
produce dsRNA molecules of any length (Makeyev 2000). The final steps of siRNA swarm 
production involve the use of a recombinant eukaryotic Dicer enzyme to digest the long dsRNA 
molecules into smaller functional siRNAs that are specific to their target (Romanovskaya et al. 
2012). These siRNAs are then purified with anion exchange chromatography followed by desalting 




Figure 5. Steps of the enzymatic production of siRNA swarms. Pools or swarms of siRNAs can be 
synthesized by PCR production from DNA templates containing the target site for silencing. A) One 
way to do this is with use of forward and reverse primers that contain the promoter sequence for 
the T7 DdRp at their 5’ end. The T7 polymerase then transcribes the DNA templates into ssRNA 
molecules which require heating at a high temperature for the denaturing of secondary and 
tertiary structures if proper annealing of ssRNAs into dsRNAs is desired. Even so denaturing 
branched structures and hairpins becomes increasingly difficult with long ssRNA molecules which 
decreases the yield of full-length, biologically functional dsRNAs. B) Alternatively, PCR production 
of DNA templates can be achieved by switching the promoter sequence of the reverse primer from 
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a T7 DdRp sequence to a Phi6 RdRp sequence. By doing so Phi6 polymerase replicates the second 
strand of the ssRNA molecule that T7 polymerase has transcribed from the DNA template in a 
single tube reaction. In both approaches (A and B) the newly synthesized dsRNAs are purified, 
cleaved by an enzyme belonging to the RNAse III family such as Dicer and further processed 
depending on the downstream application. The second approach (B) however has the advantage of 
producing a higher yield of biologically functional, full-length dsRNA molecules due to the use of 
Phi6 polymerase which removes the annealing step of the first approach (A). (Levanova and 
Poranen 2018) 
 
1.3.2 siRNA swarm targets in HSV 
 
The siRNA swarms used in this study were specifically developed against the HSV-1 genes UL27, 
UL29 and UL54. These genes are all essential for the survival of the virus, making them ideal 
targets for an RNAi based antiviral treatment, and they represent the three regulatory groups of 
HSV genes denoted alpha, beta and gamma. UL54 codes for a multifunctioning protein and 
represents the alpha group. The beta group is represented by UL29, which codes for a protein that 
partakes in DNA replication. Finally, the gamma group is represented by UL27, which is a gene 
coding for glycoprotein B that participates in virion entry. Aside from being essential genes and 
representing different regulatory groups, the genomic regions of these genes contained long 
enough target sequences for siRNA swarm development. The target sites did not share homology 
between human or mouse transcriptomes but had the advantage of being highly homologous 
between HSV-1 and HSV-2, as HSV-2 also contains the genes UL27, UL29 and UL54.  
(Romanovskaya et al. 2012; Paavilainen et al. 2016.)  
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2 Aim of the study 
 
It has been estimated that in 2016 approximately 3,8 billion and 491,5 million people globally 
carried an infection by HSV-1 and HSV-2 respectively (James et al. 2020). The detrimental effects 
of HSV can be far-reaching as the virus causes life-long latent infections that can lead to further 
complications such as infections in the ocular tissue, the CNS and as well as generalized infections 
in neonates and immunocompromised individuals (Hukkanen and Seppänen 2020). Additionally, 
HSV-2 infections increase HIV transmission which causes the spread of acquired immunodeficiency 
syndrome (AIDS), a severely harmful disease itself (Looker et al. 2017). While acyclovir is a fairly 
effective and commonly used drug for the treatment of HSV infections, ACV resistance ranges 
from 3.4% to 10% in immunocompromised patients (the prevalence in immunocompetent 
patients is 0.1 – 0.6%) (Christophers et al. 1998; Piret and Boivin 2011). According to some surveys 
resistance in immunocompromised individuals could be even higher (Langston et al. 2002; Morfin 
et al. 2004). All these facts taken together indicate that it is imperative that new drugs and 
treatments are developed to combat HSV infections worldwide.  
Previously Paavilainen et al. (2012; 2016) have developed enzymatically synthesized siRNA swarms 
targeting the essential viral HSV genes UL27, UL29 and UL54. The swarms were designed against 
the HSV-1 prototype virus strain 17+. All swarms were shown to have an inhibitory effect on HSV-
1, with the UL29 targeting swarm having the highest antiviral efficacy in both in vitro and in vivo 
studies with minimal adverse side effects (Paavilainen et al. 2016, 2017). The UL29 swarm was 
thus proven to be the best candidate for further drug development. Very few studies have been 
conducted on the efficacy of siRNA swarms against HSV-2, even though both HSV viruses contain 
the three highly homologous genes UL27, UL29 and UL54. It is undeniable that an siRNA drug 
which can effectively inhibit both HSV-1 and HSV-2 would be an ideal drug candidate, especially 
for patients suffering from acyclovir resistance.  
Because previous research has centered around HSV-1, my thesis will focus on evaluating the 
antiviral effects of the previously described UL27, UL29 and UL54 gene targeting siRNA swarms 
against clinical strains of HSV-2. The studies begin with the use of BLAST and MSA tools for in silico 
analyses of the sequence identity and conservation level of HSV-2 gene target sites of the siRNA 
swarms compared to corresponding sites in HSV-1 strain 17+. The analyses include seven fully 
sequenced clinical isolates, three reference strains and five clinical HSV-2 isolates, which I cultured 
and arranged the partial sequencing of.  The results of the sequence identity analyses are used to 
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predict the results of the antiviral experiments. After this Vero cell culture is used for the 
propagation and titration of HSV-2 strains, which will determine the virus production of viral 
stocks in plaque forming units (pfu). The actual antiviral experiments are carried out on microtiter 
well-plates in two representative cell lines, HaCaT and mink lung cells (MLC) where cells will be 
transfected with antiviral siRNA swarms or controls and later infected with an HSV-2 strain under 
study. A commercially available siRNA that has been specifically designed by Palliser et al. (2006) 
to combat HSV-2 infections is used as a positive control in the study. The effects of siRNAs on viral 
gene expression and replication are determined by 1) calculating the pfu of the produced virus 
after transfection and by 2) isolating DNA from the supernatant of treated cells and performing 
quantitative PCR analysis for the HSV-2 gD gene, which will determine the genome copy number. 
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3 Materials and methods 
 
3.1 Cell lines and viruses 
 
Antiviral studies were conducted in two cell lines, human epithelial keratinocyte (HaCaT) cells and 
mink lung cells (MLC). Cells were maintained in DMEM with 2 mM L-glutamine and 7% heat 
inactivated foetal bovine serum (FBS). Virus propagation and plaque titration was carried out in 
African green monkey (Vero) cells which were maintained in DMEM supplemented with 2% FBS 
during infection steps or 7% FBS during maintenance. All cell lines were incubated at +37 °C in 5% 
CO2.  
One reference strain of herpes simplex virus type 2 (Human herpesvirus 2, genus Simplexvirus, 
family Herpesviridae), denoted HSV-2 G, and nine clinical strains were used in the study. Clinical 
strains were obtained from herpes lesions and collected from anonymous archival diagnostic 
samples. The viral isolates were designated as #10, #24, #50, #72, #84, H1226, H12227, H1229 and 
H12211. To prepare viral stocks from clinical samples, viruses were propagated on Vero cells after 
which 9% sterile milk in water was added to infected cells. Cells were lysed by freezing and 
thawing. Viral stocks used in the study were prepared from the second passage on Vero cells by 
pelleting the infected cells to clarify the supernatants. Titers of viral stocks were determined by 
plaque titration in Vero cells on 48- or 96-well microtiter plates. Cells were infected with a virus 
under study and maintained in DMEM supplemented with 7% FBS and 0.04 mg/ml human 
immunoglobulin G. Three days post infection cells were fixed with methanol for 10 min and 
stained with 0.1% crystal violet in PBS, after which plaque forming units (pfu) from infected cells 
could be counted.  
 
3.2 Enzymatically synthesized anti-HSV siRNA swarms  
 
Anti-HSV siRNA swarms were prepared from DNA template sequences covering HSV-1 genes UL27, 
UL29 and UL54 from the HSV-1 prototype strain (17+) (GenBank JN555585). Template sequences 
were located in nucleotides 54689–55207 for the UL27 gene, 59301–59953 for the UL29 gene and 
113947–114715 for the UL54 gene in the prototype strain. PCR was used to amplify DNA 
templates using the primers listed in Table 1. Bacteriophage T7 and Phi6 polymerases were 
employed to synthesize dsRNA molecules from the PCR products in our collaborative laboratory of 
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Dr. Minna Poranen, University of Helsinki. The dsRNA molecules were then digested by Giardia 
intestinalis Dicer endonuclease to yield canonical pools or swarms of 25-27 nt long siRNAs as 
described previously (Romanovskaya et al. 2012). Finally, siRNA swarms were purified as detailed 
by Romanovskaya et al. (2012) using anion-exchange chromatography on CIMac QA columns (BIA 
Separations, Slovenia) using the AKTApurifier FPLC system (GE Healthcare). A non-specific eGFP 
siRNA swarm described by Romanovskaya et al. (2012), which has no target in HSV, was also 
included in the studies as a control.  
 
Table 1. List of primer sequences used in the study. Forward/reverse and sense/antisense primers 
were used in the siRNA swarm production, gene sequencing, PCR and quantitative PCR steps of the 
study.  
 
Primer sequences used in siRNA swam production (HSV-1 prototype sequence)  
UL27-T7 sense  TAA TAC GAC TCA CTA TAG GGC ACT TGG TCA TGG TGC AGAC  
UL27-phi6 antisense  GGA AAA AAA GGT GAT CGA CAA GAT CAA CG  
UL29-T7 forward  TAA TAC GAC TCA CTA TAG GGA TGA TGG CCG TAA GGG TGT  
UL29-phi6 antisense  GGA AAA AAA CGC AAC TTT CGC AAT CAA T  
UL54-T7 sense  TAA TAC GAC TCA CTA TAG GGC CGT CTC GTC CAG AAG ACC  
UL54-phi6 antisense  GGA AAA AAA CGG CAA AAG TGC GAT AGA G  
eGFP-T7 sense  TAA TAC GAC TCA CTA TAG GGA TGG TGA GCA AGG GCG AGG AG  
eGFP-Phi6 antisense  GGA AAA AAA CTT GTA CAG CTC GTC CAT GCC G  
Primer sequences used in sequencing  
UL27 Forward  GAG GAG AAG CGG AAG GAG C  
UL27 Reverse  CGC TAC TCC CAG TTT ATG GGG  
UL29 Forward       CCT GCA CGC TGG GGG  
UL29 Reverse      CAG TGC CAC GGG GTG TTC  
UL54 Forward   GAG ACG GAG GGG CGG A  
UL54 Reverse   GCA TGG CCT TGG CTG TCG   
Primer sequences used in qPCR  
HS2D-1U, forward  ACC CAC CGC ACC ACC ATA CTC  




3.3 Sequencing of target genes from clinical isolates 
 
Vero cells were infected with HSV-2 clinical isolates with 0.1 pfu/cell. After the CPE (cytopathic 
effect) of infection reached 100%, cells were harvested and lysed with Lyse-O-Lot (150 mM NaCl, 
10 mM Tris pH 7.6, 1.5 mM MgCl, 0.1% NP-40). The nuclei were then pelleted gently and beta-
mercaptoethanol as well as 0.5 M EDTA pH 8 was added to the supernatant. Phenol-chloroform 
extraction and ethanol precipitation was used to isolate viral DNA. To sequence genes UL27, UL29 
and UL54 from HSV-2 clinical isolates, PCR amplification was used to amplify the gene sequences 
using the primers listed in Table 1. Amplified DNA was run on a 0.8% agarose gel and the bands 
corresponding to the genes were excised and purified from the gel using GeneJet gel extraction kit 
(Thermo Fisher Scientific), following the manufacturer’s protocol. Purified DNA was then sent to 
sequencing (LightRun, Eurofins Genomics) in sealed eppendorf tubes containing an equal volume 
of DNA and primers.   
 
3.4 Transfection and infection 
 
MLC and HaCaT cells were transfected on 96-well microtiter plates at 30 – 60% confluency with 10 
pmol/well of enzymatically synthetized siRNA swarms, a single site siRNA, or water. Cells were first 
washed once with optiMEM transfection medium and transfected 1 h later using Lipofectamine 
RNAiMAX (Invitrogen) according to manufacturer’s forward transfection protocol. 4 hours post 
transfection cells were washed twice with DMEM supplemented with 2% FBS after which the same 
type of medium was used to infect cells with the HSV-2 strain under study at a dose of 1000 
pfu/well in a volume of 100 µl. 1 – 1.5 h post infection cells were washed twice and covered with 
200 µl/well of DMEM supplemented with 7% FBS. Finally, 48 h post transfection, culture media 
was collected from cells to determine viral shedding by plaque titration and quantitative PCR 
analysis.  
 
3.5 Quantitative PCR 
 
DNA was extracted from supernatants of treated cells with the NucliSens EasyMag system 
following the manufacturer’s instructions. To quantify the number of viral genomes in samples 
quantitative PCR (qPCR) was performed to amplify extracted DNA for the HSV-2 gD gene with the 
primers listed in Table 1. Reactions were carried out with the Maxima SYBR Green/ROX qPCR 
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Master Mix and the Rotor-Gene Q real-time instrument (Qiagen). The enzyme mixture was 
pipetted in a separate PCR clean room, where no PCR products or samples were handled. The total 
reaction volume was 20 µl containing 10 µl of SYBR Green/ROX qPCR master mix, 10 pmol of 
forward and reverse primers, 7 µl of water and 2 µl of DNA sample. The reaction was carried out 
as follows: initial denaturation at 95 °C for 10 min, 45 cycles at 95 °C for 15 s, 60 °C for 30 s, 72 °C 
for 45 s, followed by melting curve generation from 72 to 95 °C for 90 s and then 5 s.    
 
3.6 Computational analyses 
 
Multiple sequence alignments were performed with BLAST (Basic Local Alignment Search Tool) to 
check the identity of antiviral siRNA swarms target sites in HSV-1 strain 17 + and the 
corresponding targets in several HSV-2 strains. Primer-BLAST was used to design primers for the 
sequencing of genes UL27, UL29 and UL54 from HSV-2 clinical strains. The CAP3 Sequence 
Assembly Program was utilized to assemble contigs from data gained from sequencing of genes 
UL27, UL29 and UL54. IBM SPSS Statistics 25 software was used for statistical analyses. Two 
groups were compared at a time to calculate statistical significances using the non-parametric 





4.1 Multiple sequence alignment analysis of target genes in HSV strains 
 
Previously our group has described the in vitro and in vivo antiviral effects of siRNA swarms that 
target essential HSV-1 viral genes UL27, UL29 and UL54. These swarms were produced using target 
sites of the HSV-1 strain 17+ (GenBank JN555585) as a reference. To predict whether these HSV-1 
targeting siRNA swarms would silence the corresponding HSV-2 genes and thus inhibit the virus, 
the sequence identity of swarm target sites in HSV-1 and clinical HSV-2 strains were compared to 
each other. BLAST sequence alignments were run by aligning three HSV-2 reference strains (G, 
HG52, 333), seven fully sequenced (H1226, H1227, H1229, H12211, H12212, H1421 and H1526) 
and five partially sequenced (#10, #24, #50, #72 and #84) HSV-2 local clinical strains against the 
swarm target sites in HSV-1 strain 17+ for the genes UL27, UL29 and UL54. Alignment results 
revealed that the target site for the UL29 siRNA swarm in HSV-2 strains were the most identical to 
the swarm target site in HSV-1 strain 17+ with 97-100% query cover and 95% identity (Table 2). 
The UL27 gene target site had 100% query cover across all tested HSV-2 strains and resulted in 
94% sequence identity. The least identical target site was in the UL54 gene with 94 – 99% query 




Table 2. BLAST sequence alignment of anti-HSV siRNA swarm target sites in HSV-1 and HSV-2. 
The anti-HSV siRNA swarm target sites for the essential genes UL27, UL29 and UL54 in HSV-1 strain 
17+ were aligned to corresponding target sites in several HSV-2 laboratory and clinical strains. 
Alignment results are represented as query cover (QC) and identity (%) for each gene. 
 
HSV-2 Strain QC UL27 QC UL29 QC UL54 
G (US) 100% 488/519 (94%) 100% 621/653 (95%) 99% 599/767 (78%) 
HG52 (Scotland) 100% 488/519 (94%) 100% 619/653 (95%) 99% 601/767 (78%) 
333 100% 489/519 (94%) 100% 621/653 (95%) 99% 601/767 (78%) 
H1226 100% 488/519 (94%) 100% 620/653 (95%) 99% 601/767 (78%) 
H1227 100% 489/519 (94%) 100% 619/653 (95%) 99% 600/767 (78%) 
H1229 100% 488/519 (94%) 100% 621/653 (95%) 99% 601/767 (78%) 
H12211 100% 489/519 (94%) 100% 621/653 (95%) 99% 601/767 (78%) 
H12212 100% 488/519 (94%) 100% 621/653 (95%) 99% 601/767 (78%) 
H1421 100% 488/519 (94%) 100% 621/653 (95%) 99% 601/767 (78%) 
H1526 100% 488/519 (94%) 100% 621/653 (95%) 99% 600/767 (78%) 
#10 100% 488/519 (94%) 98% 614/645 (95%) 94% 550/729 (75%) 
#24 100% 488/519 (94%) 99% 620/652 (95%) 99% 601/767 (78%) 
#50 100% 487/519 (94%) 100% 621/653 (95%) 99% 598/764 (78%) 
#72 100% 487/519 (94%) 97% 605/639 (95%) 94% 574/725 (79%) 
#84 100% 487/519 (94%) 100% 620/653 (95%) 99% 598/767 (78%) 
 
4.2 Antiviral efficacy in MLC and HaCaT cells 
 
4.2.1. Virus titers in culture medium 
 
To analyze the antiviral effects of HSV-1 targeting siRNA swarms on clinical strains of HSV-2, HaCaT 
cells and mink lung cells (MLC) were seeded on 96-well plates and transfected with 10 pmols of 
anti-HSV swarms or controls once cells reached 60% confluency. (Lower confluency allows for 
easier and more successful transfection.) Swarms were denoted UL27, UL29 and UL54 according 
to the genes they target. A previously published HSV-2 UL29 gene targeting single site siRNA 
denoted UL29.2 was used as a reference. A non-specific siRNA swarm targeting eGFP as well as 
water transfection were used as controls. After transfections cells were infected with HSV-2 
clinical strains H1226, H1227, H1229, H12211, #10, #24, #50, #72 or #84 with a dose of 1000 
pfu/well. To quantify viral inhibition 48 hours post transfection, cell culture supernatants were 




UL27, UL29 and UL54 gene targeting siRNA swarms all had varying degrees of an inhibitory effect 
on different HSV-2 strains in both HaCaT cells and MLC. The antiviral effects were more visible in 
MLC where plaque titration showed that in almost all cases infected, antiviral swarm treated cells 
shed significantly less virus than infected and water transfected or infected only cells (Fig. 6). 
Decreases in viral shedding ranged from 10-fold to even over a 100-fold. The antiviral effects of 
swarms are better visualized as inhibition rates by comparing infected, antiviral swarm treated 
cells to infected, mock-treated cells. In MLC UL27, UL29 and UL54 gene targeting swarms all 
reached from 70 to nearly 100% inhibition rates depending on the HSV-2 strain in question (Fig. 8).  
In HaCaT cells the antiviral UL27, UL29 and UL54 siRNA swarms had a much less pronounced 
inhibitory effect on different HSV-2 strains. This was evidenced by the little to no difference in viral 
shedding of infected, swarm treated cells compared to infected, mock-treated and infected only 
cells (Fig. 7), as well as the relatively low inhibitory rates of antiviral swarms (Fig. 9). The UL27, 
UL29 and UL54 swarms that did have an inhibitory effect on some HSV-2 strains, namely #10 and 
#50 had inhibition rates ranging from 25 to 75%. 
Interestingly the single site UL29 gene targeting siRNA UL29.2 had a significant antiviral effect on 
some HSV-2 clinical isolates in HaCaT cells as well as in a few HSV-2 strains in MLC. The inhibition 
rate of the UL29.2 single site siRNA was much higher than those of the antiviral siRNA swarms in 
HaCaT cells, where the inhibition rate of UL29.2 ranged from 75 to 95% when the effect was 
significant (Fig. 9). In MLC however the antiviral UL27, UL29 and UL54 siRNA swarms reached 
higher inhibitory rates more consistently than the single site UL29.2 siRNA, whose inhibition rate 
ranged between 19% and 99% and more specifically 82 – 99% when the inhibitory effect was 
significant (Fig. 8).  
While the non-specific eGFP siRNA swarm does not contain a target site in HSV-2 it did exhibit an 
inhibitory effect on several HSV-2 strains in both HaCaT cells and MLC. In HaCaT this antiviral 
effect could be seen in three strains, where the inhibition rate of the eGFP swarm ranged between 
2 and 61% (Fig. 9). In MLC however it was surprising that the eGFP swarm could inhibit the virus 
almost at the same rate as the antiviral UL27, UL29 and UL54 siRNA swarms, as its inhibition rate 















Figures 6 – 9. The antiviral effects of enzymatically synthesized siRNA swarms in two virus 
infected cell lines. The swarms target the essential HSV-2 genes UL27, UL29 and UL54 in MLC (Fig. 
6 and 8) and HaCaT cells (Fig. 7 and 9) infected with one reference strain (G) or clinical isolates 
(#10, #24, #50, #72, #84, H1226, H1227, H1229, H12211) of HSV-2. Cells were also transfected with 
a non-specific eGFP swarm, a single site siRNA UL29.2 or water. The effects of siRNA swarms were 
determined by plaque titration in Vero cell culture from mink lung or HaCaT cell culture 
supernatants collected 48h post transfection. The results are presented as viral shedding in plaque 
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forming units (Fig. 6 – 7) and as relative inhibition rates (Fig. 8 – 9) of swarms and controls 
compared to infected, mock-treated cells (H2O), * = p<0,05. 
 
Because in some earlier experiments the UL27, UL29 and UL54 siRNA swarms had had a much 
higher antiviral efficacy in HaCaT cells, I suspected that the swarms were not being transfected 
into cells effectively. To test this hypothesis, the antiviral experiments were repeated with HaCaT 
cells using two HSV-2 strains, G and #72, and a lower cell confluency, 30% instead of the usual 60% 
used in previous studies. Cells were transfected with antiviral siRNA swarms (UL27, UL29 and 
UL54), the single site siRNA UL29.2 and controls (eGFP and water) and infected with the 
aforementioned HSV-2 strains 4 hours post transfection as was done in previous studies. In this 
experiment transfection appeared to be more successful as viral shedding decreased significantly 
in HaCaT cells treated with antiviral swarms compared to infected only and infected, mock-
transfected cells (Fig. 10). The inhibition rate of swarms ranged between 79 and 93% (Fig. 11). As 
in previous experiments the single site UL29.2 siRNA had a higher inhibition rate than the antiviral 
swarms ranging from 92 to 94%. The non-specific eGFP swarm had the lowest inhibition rate 
ranging from 54 to 77%. 
All in all, plaque titration results obtained from MLC and from the subsequent HaCaT experiments 
largely mirrored the predictions made based on the bioinformatics analyses. The UL27, UL29 and 
UL54 siRNA swarms were indeed all effective against the tested HSV-2 strains as is reflected in the 
high inhibition rates. However, results from the first HaCaT experiment were not in line with 
predictions of the swarms’ efficacy, as inhibition rates were low and observed for only 3 of the 5 








Figures 10 – 11.  The antiviral effects of enzymatically synthesized siRNA swarms in virus infected 
cells. The swarms target the essential HSV-2 genes UL27, UL29 and UL54 in HaCaT cells infected 
with one reference strain (G) or one clinical isolate (#72) of HSV-2 when cell confluency is at 30%. 
Lower cell confluency was used to determine whether HaCaT cells would be more readily 
transfected and thus the effect of antiviral siRNA swarms would be higher. In addition to antiviral 
swarms, cells were also transfected with a non-specific eGFP swarm, a single site siRNA UL29.2 or 
water. The effects of siRNA swarms were determined by plaque titration in Vero cell culture from 
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HaCaT cell culture supernatants collected 48h post transfection. The results are presented as viral 
shedding in plaque forming units (Fig. 10) and as relative inhibition rates (Fig. 11) of swarms and 
controls compared to infected, mock-treated cells (H2O), * = p<0,05. 
 
4.3 qPCR results in MLC and HaCaT cells 
 
To validate the results of antiviral studies conducted in HaCaT cells and MLC using several clinical 
HSV-2 strains and anti-HSV siRNA swarms, qPCR analysis was performed on cell supernatants 
collected 48 hours post transfection. Prior to this, cells had been first transfected with antiviral 
siRNA swarms targeting the essential viral genes UL27, UL29 and UL54 (swarms are also denoted 
UL27, UL29 and UL54), a non-specific eGFP swarm, a single site siRNA targeting the gene UL29 
called UL29.2 or water. 4 hours post transfection cells were infected with a reference strain (HSV-2 
G) or a clinical HSV-2 isolate (H1226, H1227, H1229, H12211, #10, #24, #50, #72 or #84).  
qPCR analysis yielded somewhat similar results to plaque titrations for select HSV-2 strains. In MLC 
several of the infected, UL27, UL29 and UL54 siRNA swarm treated cells appeared to have more 
HSV-2 gD gene copy numbers than infected only or infected, mock-treated cells, which means that 
swarm treated samples contained more virus (Fig. 12). The strains for which the antiviral swarm 
treatments seem to have been effective were HSV-2 G, #24, #50, #72 and #84, where inhibition 
rates ranged from 28 to 91% (Fig. 14). In cases where antiviral UL27, UL29 and UL54 swarms were 
effective in HaCaT cells, HSV-2 gD copy numbers were two to three-fold lower than infected, 
mock-treated cells (Fig. 13). Inhibition rates for antiviral swarms ranged from 3 to 73% for HSV-2 
strains #10, #24, #50 and #72 (Fig. 15). 
When comparing MLC titration results to qPCR analysis done for the same cell line, the single site 
siRNA UL29.2 had an inhibitory effect on more HSV-2 clinical strains than the antiviral siRNA 
swarms. The UL29.2 siRNA induced a two-fold decrease in HSV-2 gD gene copy numbers compared 
to infected, mock-treated cells (Fig. 12) and its inhibition rate for all HSV-2 strains ranged from 29 
to 99% and more specifically 74 – 99% for six of the ten tested viral strains (Fig. 14). Somewhat 
similarly in HaCaT cells the single site siRNA had an antiviral effect on 4 of the 5 tested HSV-2 
clinical isolates where inhibition rates ranged from 21 to 85 % (Fig. 15). For HSV-2 #10 and #50 the 
UL29.2 siRNA was more effective at inhibiting the virus than the UL27, UL29 and UL54 swarms.  
As with the MLC titration results, qPCR analysis indicated the non-specific eGFP swarm had an 
antiviral effect on HSV-2 in MLC but only on 4 of the 10 tested HSV-2 strains as opposed to all 
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strains according to the titration results. The inhibition rates for these four HSV-2 strains ranged 
from 15% to 87% (Fig. 14). In HaCaT cells the eGFP swarm had an inhibitory effect on all tested 


















Figure 12 – 15. The antiviral effects, determined by qPCR, of enzymatically synthesized siRNA 
swarms in two virus infected cell lines. The swarms target the essential HSV-2 genes UL27, UL29 
and UL54 in MLC (Fig. 12 and 14) and HaCaT (Fig. 13 and 15) cells infected with a reference strain 
(G) or one of several clinical isolates (#10, #24, #50, #72, #84, H1226, H1227, H1229, H12211) of 
HSV-2. Cells were also transfected with a non-specific eGFP swarm, a single site siRNA UL29.2 or 
water. The effects of the siRNA swarms were determined by qPCR for the HSV-2 gD gene DNA from 
mink lung or HaCaT cell culture supernatants collected 48h post transfection. The results are 
presented as HSV-2 gD DNA copy numbers in antiviral swarm (UL27, UL29 and UL54) or control 
(UL29.2, eGFP and H2O) treated and infected only cells (Fig. 12 – 13) and as relative inhibition 
rates of swarm and control treated samples compared to infected mock-treated (H2O) cells (Fig. 14 
– 15), * = p<0,05. 
 
As mentioned before, the antiviral experiments were repeated in HaCaT cells with a lower cell 
confluency (30%) to see whether cells would be transfected more efficiently and whether antiviral 
siRNA swarms would have a higher inhibitory effect on HSV-2 strains as a result. According to qPCR 
analysis all anti-HSV siRNA swarms had a significant inhibitory effect on the HSV-2 strains as, the 
HSV-2 gD gene copy numbers decreased by nearly tenfold compared to infected, mock-treated 
cells for both HSV-2 G and #72 (Fig. 16). The inhibition rates of the UL27, UL29 and UL54 swarms 
ranged between 88 and 95% (Fig. 17). The single site siRNA UL29.2 was only slightly more effective 
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at inhibiting both HSV-2 strains with its inhibition rates being 92 and 98%. The non-specific eGFP 
swarm also had an inhibitory effect on the viral strains, with HSV-2 gD copy numbers decreasing 4 
to 8-fold from infected mock-treated cells (Fig. 16). At 74 and 89% the inhibition rates for the eGFP 
swarm were lower than those of the anti-HSV swarms and the single site UL29.2 siRNA (Fig. 17).  
Collectively qPCR results from both MLC and HaCaT experiments were in line with predictions 
made using bioinformatics analyses to a varying degree. Much like the plaque titration results 
from the second HaCaT experiment, qPCR analysis yielded a similar outcome, where inhibition 
rates for the antiviral siRNA swarms UL27, UL29 and UL54 were high against both tested HSV-2 
strains (G and #72.). The first HaCaT experiment yielded moderate inhibition rates for the antiviral 
swarms against 4 of the 5 of the tested HSV-2 strains (#10, #24, #50 and #72) but the rates were 
lower than expected based on predictions. Lastly for MLC the UL27, UL29 and UL54 swarms were 
effective against 5 of the 10 tested HSV-2 strains (G, #24, #50, #72 and #84) at best, while 









Figure 16 – 17. The antiviral effects, determined by qPCR, of enzymatically synthesized siRNA 
swarms in virus infected cells. The swarms target the essential HSV-2 genes UL27, UL29 and UL54 
in HaCaT cells infected with a reference strain (G) or one clinical isolate (#72) of HSV-2 when cell 
confluency is at 30%. Lower cell confluency was used to determine whether HaCaT cells would be 
more readily transfected and thus the effect of antiviral siRNA swarms would be higher. Cells were 
also transfected with a non-specific eGFP swarm, a single site siRNA UL29.2 or water. The effects of 
siRNA swarms were determined by qPCR for the HSV-2 gD gene DNA from HaCaT cell culture 
supernatants collected 48h post transfection. The results are presented as HSV-2 gD DNA copy 
numbers in antiviral swarm (UL27, UL29 and UL54) or control (UL29.2, eGFP and H2O) treated and 
infected only cells (Fig. 16) and as relative inhibition rates of swarm and control treated samples 





HSV-1 and HSV-2 pose a significant burden on the human population with the number of people 
infected by these viruses exceeding several billion worldwide (WHO 2020). A novel treatment 
method which utilizes enzymatically synthesized siRNA swarms has previously been used to inhibit 
HSV-1 strains by targeting the essential viral genes UL27, UL29 and UL54 in vitro and in vivo with 
promising results (Paavilainen 2017). Prior to that, a single site siRNA targeting the gene UL29 had 
been developed to inhibit HSV-2 (Palliser et al. 2006). Because the use of siRNA pools offers 
several benefits over single site siRNAs and because HSV-2 contains the same genes that were 
targeted by siRNA swarms in earlier studies, it would be convenient from a therapeutic standpoint 
if the same siRNA swarms could inhibit clinical HSV-2 strains. This way one RNAi based drug could 
be developed to treat infections caused by either of the HSV viruses.  
Bioinformatics tools were used to predict the antiviral effect of enzymatically synthesized siRNA 
swarms on HSV-2 by comparing the sequences of siRNA swarm target sites in HSV-1 strain 17+ to 
corresponding sites in several clinical and laboratory strains of HSV-2 using multiple sequence 
alignment tools. To test the actual antiviral effects of swarms against HSV-2 clinical strains, siRNA 
swarms were transfected into MLC and HaCaT cells with a dose of 10 pmol prior to infection and 
supernatants were later titered to establish the viral titer in plaque forming units. A UL29 gene 
targeting single site siRNA, previously developed by Palliser et al. (2006) to combat HSV-2 
infections, was also included in the study as a positive control.  
Based on plaque titration results in HaCaT cells, in most cases UL27, UL29 and UL54 gene targeting 
siRNA swarms did not have a significant antiviral effect on HSV-2, which was in contrast with 
results obtained from MLC antiviral experiments. This raised the suspicion that siRNA swarms 
were not being effectively transfected into HaCaT cells, which prompted me to repeat the study 
using lower cell confluency. Thus 30% confluent HaCaT cells were transfected with the same anti-
HSV siRNA swarms, single site siRNA, non-specific swarm or water and later infected with HSV-2 
strain G and clinical isolate #72. In addition to plaque titration the effects of antiviral swarms on 
HSV-2 strains were confirmed through qPCR analysis, where supernatants collected 48 post 
transfection were amplified for the HSV-2 gD gene. 
Bioinformatics analysis revealed that the UL29 siRNA swarm target site in HSV-1 strain 17+ was 
most identical to its counterparts in the tested HSV-2 strains with 95% sequence identity, followed 
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by target sites for the UL27 and UL54 gene targeting swarms that had 94% and ~78% sequence 
identity respectively (Table 2). Based on these results I predicted that the UL27 and UL29 gene 
targeting siRNA swarms would have the highest antiviral effect on HSV-2 strains with little 
difference in their efficacy when compared to each other. The UL54 targeting swarm would have 
the least efficacious antiviral effect and there would be a visible difference in its ability to inhibit 
HSV-2 strains compared to the other two swarms.  
Somewhat contrary to the aforementioned predictions, all anti-HSV siRNA swarms proved 
effective at inhibiting HSV-2 clinical isolates in MLC according to plaque titration results. This was 
proven by the decrease in viral titer (Fig. 6) and by inhibition rates reaching over 90% in almost all 
studied cases for all antiviral swarms (Fig. 8). Thus, the UL54 targeting swarm was not considerably 
less effective at inhibiting HSV-2 compared to the other swarms. As predicted, compared to the 
other anti-HSV siRNA swarms the UL29 targeting swarm reached higher inhibition rates more 
consistently for individual HSV-2 strains, but the difference in inhibition rates between the 
different anti-HSV swarms was minor. 
Initially in HaCaT cells, contrary to what bioinformatics analyses suggested, swarms did not exhibit 
antiviral efficacy against all studied HSV-2 strains and when they did they reached lower inhibition 
rates (6 – 76%) than in MLC (Fig. 9). In the subsequent HaCaT antiviral study performed with lower 
cell confluency titration results showed that inhibition rates from antiviral swarms ranged from 79 
to 93% (Fig. 11). These results were more in line with ones obtained from MLC antiviral studies 
and with predictions made using bioinformatics tools. Overall, based on plaque titration results no 
swarm could be declared a clear winner at inhibiting HSV-2 in either HaCaT cells or MLC, as no 
remarkable difference in their performance was observed. 
Interestingly, according to titration results, in MLC the UL29 gene targeting single site siRNA 
UL29.2 was visibly less effective at inhibiting HSV-2 than the siRNA swarms. The single site siRNA 
only reached significant levels of viral inhibition for 5 out of 10 HSV-2 strains (Fig. 8). Contrary to 
MLC however, in the initial HaCaT cell antiviral study the single site siRNA UL29.2 was more 
effective at inhibiting HSV-2 than any of the tested antiviral swarms (Fig. 9). The same result was 
observed in the subsequent HaCaT cell study where the single site siRNA was still more effective at 
inhibiting both HSV-2 #72 and G than the antiviral siRNA swarms but with a much less pronounced 




According to qPCR analysis on the other hand, the single site siRNA UL29.2 had an antiviral effect 
on all HSV-2 strains except for strain G in MLC (Fig. 14). In the initial HaCaT antiviral experiment 
qPCR analysis showed that antiviral swarms were effective against all tested HSV-2 strains except 
for #84, whereas the single site siRNA UL29.2 had an antiviral effect on #84 and all other tested 
HSV-2 strains except strain #24 (Fig. 15). In the subsequent HaCaT cell study performed with lower 
cell confluency qPCR analysis showed that the UL27, UL29 and UL54 gene targeting swarms and 
the single site siRNA UL29.2 were all effective against the two tested HSV-2 strains (G and #72) 
(Fig. 17). In contrast to the MLC and HaCaT titration results, according to qPCR analysis the UL29 
siRNA swarm did not perform better than any other swarm nor was there any consistent patterns 
visible in the results in the case of HaCaT cells. In MLC, when swarms exhibited antiviral effects the 
UL54 gene targeting swarm reached slightly higher inhibition rates compared to the two other 
siRNA swarms (Fig. 14).  
There was a seeming discrepancy between plaque titration and qPCR results obtained from both 
MLC and HaCaT antiviral studies, discussed already above. One important factor that may have 
affected the qPCR results is the one nucleotide mismatch in the HSV-2 gD reverse primer (HS2D-
4U). The mismatch is in the 10th position from the 5’ end of the primer where guanine in the 
primer is cytosine in the HSV-2 strains. Even single mismatches between primers and their target 
sequences are known to produce errors in qPCR results though this is less likely to occur when 
mismatches appear in the 5’ end of the primer (Whiley and Sloots 2005). 
As an example of discrepancies, in MLC qPCR results showed that antiviral siRNA swarms UL27, 
UL29 and UL54 had an antiviral effect on about half of the tested HSV-2 strains (Fig. 14), while 
titration results indicated that all swarms had a statistically significant and high antiviral effect on 
all tested HSV-2 strains with only a few exceptions (Fig. 8).  In the initial HaCaT cell antiviral 
experiment the reverse was observed where qPCR results indicated that antiviral siRNA swarms 
had an inhibitory effect on 4 out of 5 tested HSV-2 strains (Fig. 15) while plaque titration showed 
that antiviral efficacy was observed in 3 out of the 5 tested HSV-2 strains (Fig. 9). Additionally, in 
the initial HaCaT experiments the inhibitory effect of swarms was generally lower than that seen in 
the qPCR analysis and overall, the siRNA swarm with the highest inhibitory effect on HSV-2 
differed between titration and qPCR results. Interestingly the least amount of discrepancy 
between plaque titration and qPCR analysis was seen in the subsequent HaCaT antiviral study 
performed with lower cell confluency (Fig. 11 and 17). It must be noted however, that the qPCR 
for HSV DNA does not measure viral infectivity but only the presence of the US segment of the viral 
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DNA where the qPCR target, the HSV-2 gD gene, resides. Thus, the release of infectious virus is 
reflected in the titration results.  
It was unexpected that the non-specific siRNA swarm eGFP, which does not target any sequence in 
HSV, had a relatively high inhibitory effect on HSV-2 in both HaCaT and MLC according to titration 
results. In MLC the eGFP swarm had a statistically significant antiviral effect on all HSV strains and 
inhibition rates ranged between 82 and 100% (Fig. 8). In HaCaT cells the antiviral effect of the 
eGFP swarm was present in 3 of the 5 of HSV-2 strains in the initial study (Fig. 9) and in both HSV-2 
strains in the subsequent study (Fig. 11). However, the antiviral effect was statistically significant 
only for HSV-2 #50 and for HSV-2 G in the first and the second HaCaT antiviral experiment 
respectively. Results from qPCR analysis showed the same discrepancy as mentioned before when 
compared to plaque titration results. According to qPCR analysis in MLC eGFP had an inhibitory 
effect on 4 of the 10 tested HSV-2 strains (Fig. 14) whereas in the initial and subsequent HaCaT 
antiviral studies the eGFP swarm was effective against all tested HSV-2 strains (Fig. 15 and 17). To 
ascertain whether or not the eGFP swarm was faulty itself, another non-specific siRNA swarm 
called pET was also tested briefly alongside eGFP in MLC. The results remained the same, with the 
pET swarm yielding as high of an antiviral effect against the tested HSV-2 strains as eGFP.   
The seemingly high antiviral effect of the non-specific eGFP swarm could be the result of the 
swarm inducing innate immunity especially in MLC, which then leads to a relatively strong 
inhibition of HSV replication. The innate immunity induced by the eGFP siRNA swarm has 
previously been studied in HaCaT cells, where it did not induce significant responses as such, in 
comparison to mock treated or non-transfected samples. When studied together with HSV-1 
infection the eGFP swarm induced IFN expression similarly to the control treatments, which meant 
that the response was induced mainly by the virus. (Paavilainen et al. 2015.) Unfortunately, the 
innate immunity, especially IFN responses, could not be determined in MLC in the context of my 
study, because no qPCR test was available for markers of the mink IFN system. Thus, it remains 
plausible that the eGFP siRNA control swarm elicited high cellular responses in MLC, which limited 
viral replication and mimicked the sequence specific RNAi effect. As HSV is susceptible to IFNs in 
epithelial cells this effect could prevent us from seeing the true outcome of RNAi. 
Taken together the results indicate that inhibition of different HSV strains is dependent on the cell 
line and viral strain under study, more than on the viral gene sequence selected as the target of 
siRNA swarms. This was proven by the fact that all anti-HSV siRNA swarms had a relatively similar 
inhibitory effect on HSV-2 despite their target sequences in the virus strains varying in identity. 
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While there is an unfortunate discrepancy between results obtained from plaque titration and 
qPCR analysis, titration results are more reliable and credible because they represent the genuine 
infectious virus instead of DNA fragments. The titers of infectious virus may be lower than they 
appear in the titration results of this study, because the immunoglobulin, used to prevent the 
appearance of secondary plaques during virus culturing, does not contain as many antibodies 
against HSV-2 as against HSV-1.   
In future studies we should further elucidate the mechanism by which these antiviral siRNA 
swarms work. Studies should be conducted to determine whether the swarms induce innate 
immunity and whether their antiviral effect is caused by target gene inhibition through RNA 
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